Guidelines for Expanding Combination Prevention and Treatment Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T)
## Table of Contents

List of Figures .......................................................................................................................... ii
List of Tables ............................................................................................................................ ii
List of Boxes ........................................................................................................................... ii
Abbreviations and Acronyms ................................................................................................. iii

### Definition of Key Terms ........................................................................................................ iv

1. **Background and Rationale** ................................................................................................ 1
   1.1. **WHO Recommendations** .......................................................................................... 1
   1.2. **South Africa Context** ............................................................................................... 1
       1.2.1. **Sex Workers** ....................................................................................................... 2
   1.3. **Combination Prevention** .......................................................................................... 3
   1.4. **Test and Treat All** .................................................................................................... 4
   1.5. **Oral Pre-Exposure Prophylaxis** ................................................................................ 4
   1.6. **Implementation of PrEP and T&T** .......................................................................... 5
   1.7. **Adherence** ................................................................................................................. 5
   1.8. **Oral PrEP Drugs: TDF and TDF/FTC** ...................................................................... 5
   1.9. **HIV drug resistance** .................................................................................................. 6
   1.10. **Pregnancy And Breastfeeding** ................................................................................ 6

2. **Guiding Principles** ............................................................................................................ 8
   2.1. **Enabling and Empowering Individuals to have an Informed and Voluntary Choice of HIV Prevention** ................................................................................................................. 8
   2.2. **Increased Effectiveness and Efficiency for the HIV Programme** ................................. 8
   2.3. **Integration of PrEP across various Entry Points** ......................................................... 8

3. **PrEP Clinical Guidelines** .................................................................................................. 10
   3.1. **Enrolment for PrEP** .................................................................................................. 10
   3.2. **Contraindications for PrEP** ....................................................................................... 10
   3.3. **Eligibility for PrEP Use** ........................................................................................... 11
   3.4. **Baseline Investigations** ............................................................................................ 12
   3.5. **Prescription of PrEP drugs** ......................................................................................... 12
   3.6. **Side Effects** .............................................................................................................. 13
   3.7. **PrEP Clients Who Test HIV-Positive** ....................................................................... 13
       3.7.1. HIV-positive prior to initiation of PrEP ................................................................. 13
       3.7.2. HIV-positive after initiation of PrEP ....................................................................... 13
   3.8. **PrEP Follow Up and Monitoring** .............................................................................. 13
   3.9. **Risk Reduction Counselling** ..................................................................................... 14
   3.10. **Discontinuation of PrEP** .......................................................................................... 14
   3.11. **Reducing The Risk Of Antiretroviral Resistance** ..................................................... 15
   3.12. **Hepatitis B Management** ........................................................................................ 15

4. **Service Delivery Guidance** .................................................................................................. 17
   4.1. **Capacity Building of Healthcare Providers** ............................................................... 17
   4.2. **Follow Up and Retention in PrEP** ........................................................................... 17
       4.2.1. Provide ongoing counselling and education ............................................................... 17
       4.2.2. Promote client retention and follow-up ....................................................................... 18
4.3. Monitoring and Evaluation of Clinical PrEP Provision ........................................... 18
5. About the Development of the PrEP Guidelines ....................................................... 19
6. Appendices ................................................................................................................. 20
7. References .................................................................................................................. 21

List of Figures

Figure 1. HIV Prevalence by District, South Africa 2012 .................................................. 2
Figure 2. PrEP Screening and Initiation Algorithm ......................................................... 16

List of Tables

Table 1. Acute Viral Symptoms of HIV Seroconversion’ ................................................. 11
Table 2. Screening Investigations .................................................................................... 12
Table 3. PrEP Follow Up and Monitoring ......................................................................... 13
Table 4. Hepatitis B Immune Status and Prep Eligibility .................................................. 15

List of Boxes

Box 1. Objectives of the PrEP Guidelines ........................................................................... 8
Box 2. Examples of Risk Reduction Questions for Counselling ....................................... 10
Box 3. Eligibility Criteria for PrEP Use ............................................................................. 11
Box 4. Potential Side Effects .............................................................................................. 13
Box 5. Resistance Risk Reduction ..................................................................................... 15
Box 6. Strategies for Supporting PrEP Adherence ......................................................... 18
Box 7. Strategies for Supporting Retention and Communication ....................................... 18
# Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGYW</td>
<td>Adolescent Girls and Young Women</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral Therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral</td>
</tr>
<tr>
<td>CHW</td>
<td>Community Health Worker</td>
</tr>
<tr>
<td>FTC</td>
<td>Emtricitabine</td>
</tr>
<tr>
<td>HBsAG</td>
<td>Hepatitis B Surface Antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B Virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HPTN</td>
<td>HIV Prevention Trials Network</td>
</tr>
<tr>
<td>HTS</td>
<td>HIV Testing Services</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>Monitoring and Evaluation</td>
</tr>
<tr>
<td>MCC</td>
<td>Medicines Control Council</td>
</tr>
<tr>
<td>MDR-TB</td>
<td>Multidrug Resistant - Tuberculosis</td>
</tr>
<tr>
<td>MSM</td>
<td>Men who have sex with Men</td>
</tr>
<tr>
<td>NDOH</td>
<td>National Department of Health</td>
</tr>
<tr>
<td>PEP</td>
<td>Post Exposure Prophylaxis</td>
</tr>
<tr>
<td>PHC</td>
<td>Primary Health Care</td>
</tr>
<tr>
<td>PMTCT</td>
<td>Prevention of Mother to Child Transmission</td>
</tr>
<tr>
<td>PrEP</td>
<td>Pre-Exposure Prophylaxis</td>
</tr>
<tr>
<td>SAHIVCS</td>
<td>South Africa HIV Clinicians Society</td>
</tr>
<tr>
<td>SAHMS-FSW</td>
<td>South Africa Health Monitoring Survey of Female Sex Workers</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually Transmitted Infection</td>
</tr>
<tr>
<td>SW</td>
<td>Sex Worker</td>
</tr>
<tr>
<td>T&amp;T</td>
<td>Test and Treat</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TDF</td>
<td>Tenofovir Disoproxil Fumarate</td>
</tr>
<tr>
<td>TDF/FTC</td>
<td>Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)</td>
</tr>
<tr>
<td>VMMC</td>
<td>Voluntary Medical Male Circumcision</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
## Definition of Key Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Working Definition in these guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>ART</td>
<td>Antiretroviral therapy refers to the use of a combination of three ARV drugs to achieve viral suppression and is given for life</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral drugs refer to the medicines active against HIV</td>
</tr>
<tr>
<td>Combination HIV Prevention</td>
<td>A combination of behavioural, biomedical, and structural approaches to HIV prevention to achieve maximum impact on reducing HIV transmission and acquisition</td>
</tr>
<tr>
<td>Continuum of Care</td>
<td>A comprehensive package of HIV prevention, diagnostics, treatment, care and support services provided for people at risk of or living with HIV and their families</td>
</tr>
<tr>
<td>Gender</td>
<td>Gender requires us to ensure that health policy, programmes, services and delivery models are responsive to the needs of women, men, girls and boys in all their diversity</td>
</tr>
<tr>
<td>Gender-based violence</td>
<td>Gender-based violence - any act of physical, sexual or psychological harm or suffering, including threats of such acts, coercion or arbitrary deprivations of liberty, whether occurring in public or in private life</td>
</tr>
<tr>
<td>Healthcare provider</td>
<td>Anyone who renders healthcare: includes doctors, nurses, pharmacists, trained counsellors, and community health workers (CHW)</td>
</tr>
<tr>
<td>Priority Populations</td>
<td>Defined groups who, due to specific higher risk behaviours, are at increased risk and vulnerability to HIV. Includes sex workers, MSM, incarcerated populations, people who use drugs or alcohol, transgender populations, and AGYW.</td>
</tr>
<tr>
<td>PEP</td>
<td>Post-exposure prophylaxis of HIV infection - the preventive ARV medical treatment started immediately after exposure to HIV in order to prevent infection</td>
</tr>
<tr>
<td>PrEP</td>
<td>Pre-Exposure Prophylaxis of HIV infection is the use of antiretroviral drugs by HIV-negative people before potential exposure to prevent the acquisition of HIV. Currently PrEP refers to oral daily PrEP (tenofovir/emtricitabine or tenofovir alone) but may incorporate other formulations over time</td>
</tr>
<tr>
<td>Serodiscordant couples</td>
<td>Couples in which one partner is HIV-positive and the other is HIV-negative, and they are in an ongoing sexual relationship</td>
</tr>
<tr>
<td>Sex Worker</td>
<td>Women, men, and transgendered people, of all ages, who work in different settings with the primary intention of exchanging money for sex.</td>
</tr>
<tr>
<td>Substantial Risk</td>
<td>Substantial risk of HIV infection is defined as a population group with an HIV incidence greater than 3 per 100 person–years in the absence of PrEP</td>
</tr>
<tr>
<td>Transgender population</td>
<td>Refers to people whose gender identity and expression are different to the social expectations of gender. They may see themselves as male, female, gender non-conformist, or one of many other gender-variant categories.</td>
</tr>
<tr>
<td>Use of ARV drugs</td>
<td>Refers to the HIV prevention benefits of using ARV drugs. This can</td>
</tr>
</tbody>
</table>
for HIV prevention include preventing mother-to-child transmission of HIV (PMTCT) by treating the mother during pregnancy and breastfeeding, using ARV drugs to reduce the transmission of HIV among serodiscordant couples, using ARV drugs to prevent people from acquiring HIV when they are exposed to HIV (post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP)), and ART for HIV-positive individuals to reduce viral load.
1. Background and Rationale

1.1. WHO Recommendations

Since first published in 2002, the World Health Organization (WHO) guidelines on the use of ART have evolved. Over the years, additional evidence has emerged showing that earlier initiation of ART results in better, long-term clinical outcomes for people living with HIV, resulting in a population impact on HIV transmission. Clinical trial results have also confirmed the efficacy of the drug tenofovir disoproxil fumarate (TDF), alone or in combination with emtricitabine (FTC), for use as PrEP to prevent people from acquiring HIV in a wide variety of settings and populations\(^1\). The use of PrEP to prevent people from acquiring HIV is an important new additional prevention option for populations who are at a substantial risk of acquiring HIV.

On 30 September 2015 WHO published an early-release to the new guidelines on the use of ART for the prevention and early treatment of HIV infection. These new guidelines recommend the following:

- ART should be initiated in everyone living with HIV regardless of their CD4 cell count.
- People with a substantial risk of HIV infection should be provided with daily PrEP as part of a combined HIV prevention strategy.

1.2. South Africa Context

South Africa has the largest HIV epidemic in the world, with 6.8 million people (ages 15-49) living with HIV, representing 19% of the global HIV burden\(^1\). The South Africa HIV programme was launched in 2009 and, as of 2015, there are just over 3.3 million people on antiretroviral treatment (ART), creating the largest ART programme in the world\(^2\). Yet, despite this accelerated progress in initiating and treating HIV-positive people, there are still more than 3 million people that would need treatment in line with the 2015 WHO ART guidelines\(^3\).

The epidemic has varied significantly across and within different provinces in South Africa. Even though the epidemic is generalised, it is also over-represented in some populations, specifically Sex Workers (SW) and Men who have Sex with Men (MSM). It is also concentrated in the populations with very high vulnerability to HIV, such as adolescent girls and young women (AGYW). This comprehensive contextual understanding of the HIV epidemic is critical in order for effective HIV interventions to be developed and implemented. Differential vulnerability levels, social risk factors, high-risk sexual practices, and limited access to appropriate HIV interventions, influences HIV incidence among these populations\(^4,5,6\).

---

\(^1\) Guidelines on When to Start Anti-Retroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Sept 2015.
These guidelines will focus on the provision of pre-exposure prophylaxis (PrEP) and universal test and treat (T&T) for sex workers (SW) as part of a comprehensive combination prevention and expanded treatment policy, and should be read in conjunction with the National PrEP and T&T Policy, The South African National Sex Worker HIV Plan (2016 – 2019), the National Strategic Plan for HIV, TB AND STIs (2012 – 2016), and the National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults (2015).

1.2.1. Sex Workers

In these guidelines sex workers include: women, men, and transgendered populations, who sell sex regularly and occasionally, and those who may or may not self-identify as sex workers. Sex workers range in age, socio-economic status, and are of diverse sexual orientation and gender identities.

The 2013 rapid population size estimate reported that there were around 153,000 sex workers (including male and transgender sex workers) in South Africa\(^8\). Sex workers, including females, males, and transgendered populations, have disproportionately higher risk for HIV acquisition as behavioural, legal, and social barriers increase their vulnerability\(^9\). An estimated 20% of the 350,000 people annually infected with HIV in South Africa are connected with sex work\(^10\). HIV prevalence amongst female sex workers in South Africa is estimated to be 59.8%\(^11\). The SA Health Monitoring Survey of Female Sex Workers (SAHMS-FSW)\(^12\) estimates the prevalence of HIV among female sex workers at 71.8% in Johannesburg, 39.7% in Cape Town, and 53.5% in eThekwini. The same report observed marked increases in HIV prevalence among female sex workers as they got older, with those aged 25 years and older compared to the 16-24 age group (Johannesburg, 78.8% v. 59.0%; Durban 71.2% v. 29.4%), confirming the urgency of focused intervention for sex workers who are HIV-positive and on preventing HIV-negative sex workers from being infected.
The data from the SAHMS-FSW confirm that female sex workers carry an enormous burden of HIV: at least one-third has been infected with HIV by the age of 24; among those 25 and older, as many as 4 in 5 are HIV-positive. Fortunately, the vast majority have tested for HIV, and more than three-quarters of HIV-positive female sex workers are aware of their status. Prevalence of syphilis among female sex workers in Johannesburg and Cape Town is among the highest measured in the southern African region\(^\text{13}\). In addition, sex workers continue to experience intense stigma and discrimination, violence (including sexual assault) with poor recourse to justice, legal barriers and constraints to accessing services\(^\text{14}\).

Young sex workers may be more vulnerable to HIV than their older counterparts because of less power to negotiate condom use, greater susceptibility to violence and greater number of sexual partners due to exploitation and male age preferences\(^\text{15}\). By making PrEP and T&T available to sex workers, their HIV risk can be reduced.

The evidence for inclusion of PrEP for sex workers is strong and there are existing platforms for health care delivery specifically targeted to these high-risk, hard to reach populations. For these reasons, roll out of PrEP and T&T should be considered in this group first\(^\text{16}\). In this respect, sex workers in South Africa have been prioritized as a population at substantial risk due to lack of power to insist on condoms, high rates of gender based violence and rape, and lack of legal protection.

### 1.3. COMBINATION PREVENTION

Combination HIV prevention is an approach that seeks to achieve maximum impact on preventing new HIV infections by combining biomedical, socio-behavioural, and structural interventions that are human-rights based and evidence informed, in the context of a well-researched and understood local epidemic. The combination prevention package for SW includes: condoms, lubricants, STI management, screening and management of intimate partner violence, sexual and reproductive health services, and HIV services, including counselling and testing, HIV management, ART, PEP, and PrEP\(^\text{17}\).

Combination prevention programmes are: ...rights-based, evidence-informed, and community-owned programmes that use a mix of biomedical, behavioural, and structural interventions, prioritized to meet the current HIV prevention needs of particular individuals and communities, so as to have the greatest sustained impact on reducing new infections. Well-designed combination prevention programmes are carefully tailored to national and local needs and conditions; focus resources on the mix of programmatic and policy actions required to address both immediate risks and underlying vulnerability; and they are thoughtfully planned and managed to operate synergistically and consistently on multiple levels (e.g. individual, relationship, community, society) and over an adequate period of time. They mobilize community, private sector, government and global resources in a collective undertaking; require and benefit from enhanced partnership and coordination; and they incorporate mechanisms for learning, capacity building and flexibility to permit continual improvement and adaptation to the changing environment.

- UNAIDS Prevention Reference Group
1.4. Test and Treat All

Globally, around one-third of the 15 million individuals who are eligible for treatment are currently receiving ART\textsuperscript{18} and for each person started on ART, at least two more individuals become newly infected with HIV (*reference). This causes a continuous increase in the number of HIV-positive people who will require ART in future, in the absence of substantial reductions in HIV incidence. The WHO has recommended that ART should be initiated among all adults and children with HIV regardless of WHO clinical stage and at any CD4 cell count, prioritising those with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and adults with CD4 count ≤500 cells/mm\textsuperscript{3}. Earlier initiation of ART results in better long-term clinical outcomes for HIV-positive people and reduces an individual's viral load and hence their infectiousness.

The HIV Prevention Trials Network (HPTN) 052 study showed that starting ART early reduced the overall risk of HIV sexual transmission to uninfected partners by 93\%\textsuperscript{19}. With approximately 6.8 million people infected with HIV in South Africa, and just over 3 million on ART, there is an unmet need of approximately 50\%. T&T is proposed as a new, highly effective, HIV prevention strategy. T&T interventions are built around two main components: First, HIV testing services (HTS) are offered to all members of a defined high-risk population to identify those already infected with HIV, but not yet linked to care, and thereafter regular and repeat HIV testing of those who test HIV-negative to identify new positives as early as possible after seroconversion. Second, the initiation of life-long ART immediately after HIV diagnosis, regardless of CD4 count\textsuperscript{20, 21, 22}.

To test and treat all has the potential to cause a very steep reduction in HIV incidence, will reduce HIV-related morbidity and mortality, and could potentially eliminate HIV as a public health problem over a period of 15-20 years\textsuperscript{23}. WHO recommends that all HIV infected individuals be started on ART regardless of their CD4 count.

South Africa will adopt a phased approach in the implementation of T&T. Initial targeting of sex workers provides a tangible benefit of reducing the burden of HIV-infection. The T&T approach\textsuperscript{24} will be extended to all sex workers. HIV-positive sex workers will be offered immediate initiation on ART, regardless of CD4 count or clinical staging, in line with the National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults (2015). HIV-negative sex workers will be offered PrEP at selected sites that have met clinical and service delivery criteria.

1.5. Oral Pre-Exposure Prophylaxis

PrEP is defined by WHO as the use of antiretroviral drugs by HIV-negative people, before potential exposure to prevent the acquisition of HIV. Oral PrEP is an evidence based HIV risk-reduction intervention to be offered to all people at substantial risk of acquiring HIV\textsuperscript{25}. Substantial risk of HIV infection is defined by WHO as a population group with an HIV incidence greater than 3 per 100 person–years in the absence of PrEP\textsuperscript{26}. Defining who should be offered PrEP requires a country to balance the risk of HIV exposure, the (low) risk of serious adverse events, and available resources.
The WHO recommends that PrEP, containing tenofovir disoproxil fumarate (TDF), should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of a combination of prevention approaches that include: HTS, counselling, male and female condoms, lubricants, ART for HIV-positive partners in serodiscordant couples, and voluntary medical male circumcision (VMMC). Populations who would benefit most from PrEP are often underserved and likely to also have low levels of HIV testing and high levels of undiagnosed HIV and may need to be linked to other services.

PrEP has been shown to be safe, with minimal side effects. One of the main guiding principles for PrEP as an intervention is that it will enable and empower people to have an informed and additional voluntary choice of an HIV prevention method. The evidence and benefits of PrEP are summarized in Appendix 1.

1.6. IMPLEMENTATION OF PrEP AND T&T

To inform the implementation of PrEP and T&T among sex workers, the evidence from several demonstration projects will be used. The demonstration projects will enable the country to scale up PrEP and T&T. The platform of delivery will be through existing sex worker programmes and linked to primary health care facilities, where appropriate, with the aim of integrating them into existing public health services (refer to PrEP and T&T Implementation plan).

1.7. ADHERENCE

Adherence is important in both PrEP use and HIV treatment, and will form an integral part of the combination prevention and T&T programme. Adherence is a significant modifier of PrEP effectiveness. Effective PrEP use is different from HIV treatment in that PrEP can be started and stopped as a person moves through “seasons of risk”, whereas ART is lifelong.

Effective use of PrEP requires daily usage. It should be taken for a specified period, initially for attainment of full protection, followed by daily use for the duration of possible exposure to HIV infection, followed by a continuous use for one month after the cessation of exposure. Good quality counselling fosters adherence and supports a comprehensive plan for sexual and reproductive health.

It is important to offer a combination prevention package of services for PrEP users to further decrease risk of HIV infection. These include: VMMC, consistent and correct use of condoms, use of lubricants, and risk assessment and reduction.

1.8. ORAL PrEP DRUGS: TDF AND TDF/FTC

Tenofovir (TDF) and tenofovir/emtricitabine (TDF/FTC) in a single tablet fixed dose combination (FDC) are the oral antiretroviral agents used in oral PrEP studies to date. A systematic review and meta-analysis of PrEP trials containing TDF demonstrated that the level of protection from TDF versus TDF/FTC did not differ by age, gender, regimen, or mode
of acquiring HIV (rectal, penile, or vaginal). In a meta-analysis, conducted in May 2015, of all PrEP trials, daily oral TDF has comparable efficacy to TDF/FTC.

In clinical trials, it has been shown that the difference in efficacy between TDF/FTC and TDF alone is insignificant. However, the use of TDF monotherapy for HIV prevention has not been investigated in some key populations and on this basis, the Southern African HIV Clinicians Society (SAHIVCS) recommends the use of TDF/FTC in combination for oral PrEP.

In South Africa, as of December 2015, the TDF/FTC combination pill, also known as Truvada®, was approved for use as PrEP by the Medicine Control Council (MCC), in combination with safer sexual practices. TDF alone has not yet been approved for use as PrEP by the MCC, and to date, no applications have been made to the MCC for registration of TDF for PrEP use.

1.8.1. **Daily PrEP vs non-daily PrEP**

WHO does not currently recommend intermittent use of PrEP. The ADAPT study (HPTN 067) conducted among women in Cape Town, evaluated the feasibility of non-daily oral PrEP using Truvada²⁹. The study showed that there was better adherence and better coverage of potential sexual exposure when PrEP is taken daily. Daily adherence is more forgiving³⁰ in the case of missed doses and results in more sustained use during periods of HIV acquisition risk, as opposed to intermittent use.

1.9. **HIV Drug Resistance**

The risk of HIV drug resistance to either TDF or FTC is low, occurring in approximately 1 in 1,000 PrEP users in clinical trials, and was mainly seen in those with acute undetected HIV infection at the time of initiating PrEP. Various trials have shown that the overall implementation of PrEP is expected to decrease the public health burden of HIV drug resistance³¹, ³², ³³. Had the averted infections occurred in the absence of PrEP, more resistance would be expected to occur during the treatment of these infections than occurred due to PrEP use.

1.10. **Pregnancy and Breastfeeding**

* Please note – awaiting feedback and recommendations from the WHO March meeting. They are currently reviewing safety data from women taking TDF for HIV treatment and Hep B treatment, and at 3 PrEP studies which looked at pregnancy outcomes when PrEP was taken at conception and in early pregnancy. With feedback we will have better detail of the guidance to provide to healthcare practitioners for the provision of PrEP to these populations.

In South Africa, the currently approved form of TDF/FTC, Truvada, is contra-indicated for use as PrEP in pregnant or breastfeeding women. However, as the risk of seroconversion during pregnancy is high, the risks and benefits of PrEP should be discussed with potential PrEP users, allowing these women at high risk of HIV acquisition to make an informed decision regarding PrEP use. HIV-negative women in serodiscordant relationships are at risk of acquiring HIV infection whilst trying to conceive through unprotected sex. Pregnancy itself is
also associated with an increased risk of becoming infected with HIV\textsuperscript{34}. The use of PrEP around the time of conception and during pregnancy offers a means of protection to the uninfected partner. Unfortunately, data relating to the safety of PrEP specifically with regard to the developing foetus are limited*, and consequently the onus is on the clinician to discuss potential risks and benefits of PrEP initiation or maintenance during pregnancy with the client.

PrEP trials involving heterosexual women excluded pregnant women from enrollment, and those who fell pregnant during the conduct of the study were discontinued from PrEP. One study of 46 uninfected women in serodiscordant relationships demonstrated no adverse effects on the pregnancy or cases of HIV transmission when TDF was used around the time of conception. There are several ongoing demonstration projects that will allow women to continue PrEP if they fall pregnant, which will provide some data to inform future recommendations. In addition, the Antiretroviral Pregnancy Registry shows no evidence of adverse outcomes amongst infants exposed to these medications when used as ART in utero.
2. Guiding Principles

The use of PrEP and T&T aim to contribute to the country’s targets for HIV reduction by 2030, as reflected in the National Development Plan. South Africa supports the UNAIDS Fast Track approach, the 90-90-90 targets, and the prevention target of reducing the number of new HIV infections by 75% by 2020. To achieve these goals, there is a need for an expanded and accelerated scale up of HIV treatment and combination prevention, including PrEP.

These new guidelines will assist in providing the necessary guidance towards improved management of HIV prevention across different populations.

**Box 1. Objectives of the PrEP and Test & Treat Guidelines**

- **Expanded prevention options**: Offer and promote PrEP in the context of combination prevention.
- **Integration**: Integrate PrEP and T&T into other HIV prevention programmes, policies, and services, as well as sexual and reproductive health, contraception and fertility planning services, and ANC services.
- **Quality of care**: Provide PrEP within the broader framework of quality health service provision.
- **Communication and community based strategies**: Implement appropriate, evidence-informed, communication and advocacy strategies to increase healthcare provider and public awareness of PrEP and T&T within the context of HIV prevention without stigmatising the intervention and potential users, nor increasing risky sexual behaviour.
- **Monitoring and evaluation**: M&E systems are in place to monitor and evaluate provision, quality of care, outcomes, and impact.

*From the National PrEP and T&T Policy*

**2.1. Enabling and Empowering Individuals to have an Informed and Voluntary Choice of HIV Prevention**

These guidelines are underpinned by a rights-based approach, whereby individuals are provided with information that will enable them to voluntarily make decisions on options for HIV prevention. A rights-based approach also includes confidentiality and equal access to non-discriminatory healthcare, privacy, prevention choice, informed decision-making, and shared responsibility.

**2.2. Increased Effectiveness and Efficiency for the HIV Programme**

Two important objectives of the HIV programme are to avert new HIV infections and improve access to ART. Both PrEP and T&T will contribute to increased effectiveness of the HIV programme. Averted HIV infections translates to a reduced burden on the national health system, and each newly identified HIV-positive person treated reduces the burden on the clients and their families and communities.

**2.3. Integration of PrEP and Test & Treat across various Entry Points**
PrEP and T&T will be integrated into all the entry points of the public health system (primary healthcare (PHC) clinics, HTS, ANC, SRH services, contraception and fertility services, VMMC services, STI and TB screening, ToP services, post-rape care services, etc.) This will mitigate against stigmatisation when trying to obtain HTS and PrEP services.
3. PrEP Clinical Guidelines

The implementation of PrEP will increase the use of HTS, which will assist in getting people to know their HIV status. Those that test HIV-positive during screening should immediately be referred for HIV treatment and care. It is therefore important to establish a seamless transition between PrEP and HIV treatment programmes.

PrEP should not displace or undermine the use of other effective and well-established HIV combination prevention interventions. PrEP should be promoted as an additional prevention choice among sex workers in conjunction with other appropriate prevention methods.

For those that test HIV positive during HTS, please refer to the National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults (2015) for the appropriate treatment options.

3.1. Enrolment for PrEP

Some individuals requesting PrEP are likely to be at ongoing or substantial risk for HIV and might always fall into a window period when trying to confirm HIV status (e.g. a sex worker with recurrent daily exposures). These individuals should not be excluded from accessing PrEP, as they potentially have the most to gain from the intervention.

Risk assessment questions can be used as part of combination prevention to explore risk and risk reduction and prevention strategies.

BOX 2. Risk Reduction Counselling

Explore the following topics as appropriate:
- Avoiding unprotected sex
- Consistent and correct use of condoms
- Knowing your HIV status and your partner’s HIV status
- Are you or your partner on ART?
- Use of recreational or injection drugs for you or your client or partner
- Sex under the influence of alcohol and/or drugs
- Experience of intimate partner violence/sexual violence
- Use of ARVs to prevent HIV following unprotected sex (PEP)

Following HIV testing, if sex worker is HIV-positive, immediately refer for ART initiation. If sex worker is HIV-negative, PrEP should be offered after screening as part of a combination prevention package (refer to algorithm on page 16).

3.2. Contraindications for PrEP

The following are contraindications for PrEP use:
- Pre-existing HIV infection
Creatinine clearance of less than 60mL/min
- Adolescents <35kg or <15 years of age who are not Tanner stage 3 (sexual maturity rating) or greater
- Unwilling/unable to adhere to daily PrEP
- Pregnancy (as per Truvada package insert) *refer to section 1.10

Other important considerations include:
* TDF/FTC is active against Hepatitis B infection. Discontinuation of TDF/FTC requires close monitoring in those infected with Hepatitis B due to the concern for rebound viraemia.
* Persons with osteopenia/osteomalacia/osteoporosis may be at risk of bone loss associated with TDF.
* Women who want to conceive and are eligible for PrEP must be monitored.
* After discussing the potential risks of TDF/FTC, recommend continuation of PrEP during pregnancy or breastfeeding for those with ongoing risk for HIV exposure (refer to section 1.10).
* TDF should not be co-administered with other nephrotoxic drugs, e.g. aminoglycosides.
* Standard TB medication does not interact with PrEP drugs and there is no need for dose adjustments.
* Clients on MDR-TB medications may have increased risk of renal side effects. PrEP should therefore be avoided. Other prevention methods should be recommended and PrEP screening should be delayed until the end of MDR-TB treatment.
* Standard hormonal contraception does not affect PrEP effectiveness nor does PrEP affect contraceptive effectiveness35.
* There are currently no published studies on the use of PrEP for individuals younger than 18 years of age.
* Offer immediate treatment if PrEP user seroconverts.

3.3. Eligibility for PrEP Use

Providers should educate and counsel potential PrEP users about PrEP, which should always be provided as part of a combination prevention package.

Box 3. Eligibility Criteria for PrEP Use
- No contraindications to TDF or FTC
- HIV-negative
- No suspicion of acute HIV infection (refer to Table 1)
- Willing and able to adhere to PrEP

Table 1. Acute Viral Symptoms of HIV Seroconversion36,37

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Sign</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaise, anorexia, myalgia,</td>
<td>Fever, sweating, viral meningitis, generalised lymphadenopathy,</td>
</tr>
<tr>
<td>headache, sore throat, sore</td>
<td>hepatosplenomegaly, pharyngitis, truncal rash, orogenital herpetiform</td>
</tr>
<tr>
<td>glands, rash</td>
<td>ulceration, oral/oesophageal candidiasis, cervical adenopathy</td>
</tr>
</tbody>
</table>
If the client has symptoms or signs of acute HIV infection, PrEP should be postponed until symptoms subside and a repeat rapid HIV test after 4 weeks remains negative.

### 3.4. Baseline Investigations

#### Table 2. Clinical Screening Investigations

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV test (using algorithm in the HTS guidelines)</td>
<td>Assessment of HIV status</td>
</tr>
<tr>
<td>Creatinine clearance</td>
<td>To identify pre-existing renal disease</td>
</tr>
<tr>
<td>Hepatitis B surface antigen (HBsAg)*</td>
<td>To identify undiagnosed hepatitis B infection</td>
</tr>
<tr>
<td>ALT if HBsAg positive</td>
<td>To identify those eligible for vaccination against hepatitis B</td>
</tr>
<tr>
<td>Urine pregnancy test</td>
<td>To identify if client is pregnant</td>
</tr>
<tr>
<td>RPR</td>
<td>To diagnose syphilis infection for treatment</td>
</tr>
<tr>
<td>Syndromic STI screening</td>
<td>To diagnose and treat STI</td>
</tr>
</tbody>
</table>

* Clients with acute or chronic hepatitis B infection can be safely initiated onto PrEP but require liver function monitoring.38

* Bone density measurements are not needed

Clients with abnormal renal function (estimated creatinine clearance <60 mL/min) should not initiate PrEP and the test must be repeated after two weeks. If renal function returns to normal and other PrEP criteria are met, PrEP may be initiated.

### 3.5. Prescription of PrEP Drugs

The recommended regimen, which can be used in all populations is:

- Truvada (TDF/FTC) 1 tablet PO daily

Prescription intervals:

- At initiation – provide 1-month supply
- At 1 month – repeat HIV test and provide 3-month supply
- Every 3 months – repeat HIV test and provide 3-monthly supply

Other HIV prevention methods should be discussed and provided at all visits. Users should be advised that a negative HIV test is required before PrEP drugs can be prescribed at initiation and with every prescription refill, as well as when restarting after a discontinuation. It should be made clear that PrEP is not treatment for HIV, despite using the same medicines, and therefore it should not be shared with people who have not tested HIV negative.
Males initiating PrEP need 7 days of daily dosing to reach adequate anal/rectal tissue levels, while females need up to 20 days of daily dosing to achieve protective vaginal tissue levels of PrEP drugs. During this period, other protective precautions preferably should be used, such as abstinence or condoms.

### 3.6. SIDE EFFECTS

The major toxicities associated with TDF/FTC are rare in PrEP exposure to date. Minor side effects are relatively common but are mild and self-limiting if they do occur (approximately 1 in 10 individuals in the first 1-2 months), and do not require discontinuation of PrEP.

**BOX 4. POTENTIAL SIDE EFFECTS**

Major side effects: renal toxicity and metabolic complications (decreased bone mineral density, which is reversible in adults upon stopping PrEP), extremely small risk of lactic acidosis and hepatic steatosis or steatohepatitis

Minor side effects: gastrointestinal symptoms (diarrhoea, nausea, vomiting and flatulence), which are self-limiting and typically end within first month of use; unintentional weight loss

Less predictable side effects: hypersensitivity reactions and flares of hepatitis B in those who are chronic carriers if they stop TDF/FTC

### 3.7. PREP CLIENTS WHO TEST HIV-POSITIVE

#### 3.7.1. HIV-positive prior to initiation of PrEP

Clients who test HIV-positive must be offered ART as soon as possible, regardless of CD4 count. They must be linked to HIV care, treatment, and support. Where possible, their partners should be encouraged to test for HIV.

#### 3.7.2. HIV-positive after initiation of PrEP

HIV seroconversion after initiating PrEP can occur, and may be due to non-adherence or being in the window period at the time of testing. As soon as an HIV-positive test has been confirmed ART should be immediately initiated, using first-line regimens, and the client must be linked to HIV care and treatment. Resistance testing, or use of second-line regimens, is not recommended, as only about 3% of seroconverters who have received PrEP may have resistance to FTC or TDF.

### 3.8. PREP FOLLOW UP AND MONITORING

**TABLE 3. PREP FOLLOW UP AND MONITORING**

<table>
<thead>
<tr>
<th>Activity</th>
<th>Following PrEP Initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmation of HIV-negative status</td>
<td>At 1 month, then every 3 months</td>
</tr>
<tr>
<td>Address side effects</td>
<td>Every visit</td>
</tr>
<tr>
<td>Adherence counselling</td>
<td>Every visit</td>
</tr>
<tr>
<td>Creatinine clearance test</td>
<td>At 1 month, then every 3 months for the first year,</td>
</tr>
</tbody>
</table>
3.9. RISK REDUCTION COUNSELLING

Risk-reduction counselling is a behavioural intervention that attempts to decrease an individual’s chances of acquiring HIV and other STIs[^39], and should be implemented together with HIV prevention counselling and sexual reproductive health and contraceptive counselling at all follow-up visits for PrEP users.

The main objective of risk-reduction counselling is for clients to assess individual risk and set realistic goals for behaviour change that could reduce their risk of contracting HIV and other STIs, as well as reduce unwanted pregnancies. This is most effective when it is non-prejudicial and user-centred. Risk reduction counselling can be provided by any trained healthcare provider and should address the following points:

- Explore the context of the client’s specific sexual practices and psychosocial status, and assist client to recognise which of their behaviours are associated with higher risks for HIV infection. Healthcare providers should also be aware that clients might not always perceive their own risk, or be in denial about it.
- Identify the sexual health protection needs of the potential PrEP user and reflect on what their main concerns appear to be.
- Strategise with the client on how they can manage these concerns or needs.
- Agree on which strategies the client is willing to explore and guide them to decide on how to implement the strategy.

3.10. DISCONTINUATION OF PRÉP

PrEP should be stopped if the client:

- Has a positive HIV test
- Develops renal disease
- Is non-adherent to PrEP
- Does not need or want PrEP
- No longer meets eligibility criteria
- If there are safety concerns where the risks of PrEP use outweigh potential benefits

The duration of PrEP use may vary and individuals are likely to start and stop PrEP depending on their risk assessment at different periods in their lives. Because PrEP is user driven, users should be given information on the correct way to stop PrEP to ensure effectiveness. For users who want to stop PrEP they should do so after consultation with the

[^39]: The TAPS program will implement creatinine testing every 6 months. This additional data may provide evidence which will allow for updating the guidelines in the future.
health care provider. PrEP medication should be continued for 28 days after the last potential HIV exposure to ensure coverage and protection.

3.11. Reducing the Risk of Antiretroviral Resistance

To minimise the risks of developing ARV resistance, HIV testing must be done every three months, with a symptom screen and a targeted examination to exclude acute HIV infection. HIV testing should also be repeated whenever symptoms of a viral illness are present.

Box 5. Resistance Risk Reduction

- Feasibly exclude acute HIV infection before initiating PrEP by:
  - HIV testing before commencing or re-prescribing PrEP
  - Conduct a clinical screen to detect signs and symptoms of acute HIV infection
  - If there are suspicions of acute HIV infection, delay PrEP and investigate
- Assess adherence with every visit - enquire about pill taking patterns and missed doses
- Support client to maximise adherence and include adherence counselling at each visit
- Provide adequate supply of drugs and give consideration to the individual needs
- Revisit eligibility criteria every time the client re-starts PrEP - this must be done by the healthcare provider, not by the client
- Discontinue when client’s risk profile has changed and client is no longer at substantial risk

3.12. Hepatitis B Management

TDF and FTC both have hepatitis B antiviral activity. The potential risk exists that exposure to these antivirals may treat unidentified chronic hepatitis B infection with a consequent viral flare (rebound) upon drug withdrawal that can result in a liver injury. To avoid this risk, screening for hepatitis B surface antigen and antibodies occurs prior to PrEP commencement.

If hepatitis B surface antigen (HBsAg) is positive, the user should be investigated prior to commencement of short-term PrEP. PrEP is not contra-indicated in those with HBV but liver function monitoring should be performed. PrEP users with persistently elevated or abnormal liver function tests should be referred for assessment. Liver function tests should be checked after stopping PrEP in those with chronic hepatitis B infection. People with chronic hepatitis B infection may choose to continue using tenofovir to control their hepatitis, even if they do not require these drugs any longer for the indication of PrEP. Users with a history of injecting drug use should be screened for hepatitis C and, if positive, referred for further care.

Table 4. Hepatitis B Immune Status and Prep Eligibility

<table>
<thead>
<tr>
<th>Hepatitis B surface antigen (HBsAg)</th>
<th>Hepatitis B surface antibody (HBsAb)</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative (-)</td>
<td>Negative (-)</td>
<td>Start PrEP, vaccinate concurrently if available</td>
</tr>
<tr>
<td>Negative (-)</td>
<td>Positive (+)</td>
<td>Start PrEP, no vaccine needed</td>
</tr>
<tr>
<td>Positive (+)</td>
<td>N/A</td>
<td>Refer for evaluation</td>
</tr>
</tbody>
</table>
**FIGURE 2. PREP AND T&T SCREENING AND INITIATION ALGORITHM**

Perform HIV testing and screening (TB, STI, NCDs) as per HTS guidelines

- **HIV Negative**
  - Potentially eligible for PrEP
  - Risk reduction counselling and confirm interest in PrEP

- **Creatinine and Hepatitis B Screening (Surface antibody and antigen)**
  - Pregnancy test for women

- **If Creatinine clearance > 60ml/min**
  - Initiate PrEP

- **If creatinine clearance < 60ml/min**
  - Review in 2 weeks

- Provide one month PrEP prescription

- Provide ongoing PrEP education and counselling

- Book a follow up appointment within 28 days

**HIV Positive**
- Refer all for immediate ART initiation, regardless of CD4 count, as per HIV Guidelines

**Use rapid tests as per DOH guidelines and availability**

**Treat any present STIs**

**HIV positive: Refer to the National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults (2015).**

**Clients with acute or chronic hepatitis B can be safely initiated onto PrEP but require LFT monitoring.**
4. Service Delivery Guidance

4.1. Capacity Building of Healthcare Providers

The National Department of Health Operational Guidelines for HIV, STI, and TB Programmes for Key Populations in South Africa\(^{41}\) acknowledges the need for healthcare provider sensitisation training in order to better support public healthcare services and adolescent friendly services for priority populations.

In the context of PrEP and T&T sex worker programmes, healthcare provider sensitisation training may promote stronger uptake and retention in care by creating a non-stigmatising and supportive space for delivery of PrEP and T&T in the sex worker population. All healthcare providers involved in the provision of PrEP and ART services should be involved in such training, including doctors, clinical nurse practitioners, staff nurses, counsellors, pharmacists, pharmacy assistants, outreach workers, other healthcare providers, and peer supporters.

In addition to sensitivity and competency training for sex workers, all healthcare providers affiliated with PrEP and ART service delivery should complete a PrEP and T&T implementation training programme, including clinical management, adherence, combination prevention, and risk reduction counselling.

4.2. Follow Up and Retention in PrEP

After clients have been initiated onto PrEP, the core focus of the service provider should be on supporting retention and maintaining adherence among those using PrEP. For populations at substantial risk, there are important considerations that can affect their ability to be retained. Strategies for supporting follow up and retention are discussed in Box 6 below.

4.2.1. Provide ongoing counselling and education

At each follow up visit, providers should assess if the use of PrEP has changed for their client and the effect this may have on the effectiveness of PrEP. Providers should support the client to identify strategies for improving adherence, which take into consideration the clients’ individual barriers and facilitators. Adherence counselling should be client-centred. Barriers and facilitators to adherence should be identified by the client and not prescribed by the provider. Ongoing education and counselling should then be provided to the client at each PrEP-related visit.
**4.2.2. Promote client retention and follow-up**

Individuals may face challenges in attending regular follow-up visits required for PrEP services. Strategies should be used to address the specific challenges faced by individuals to support retention in PrEP services and adherence to PrEP. For example, sex worker populations may be highly mobile, may not consistently visit the same clinic or service provider over an extended period of time, and may find it difficult to attend clinic services during regular office hours.

**Box 6. Strategies for Supporting PrEP Adherence**

- Use alternative methods of communication: SMS, social networking, mobile applications
- Integrate mobile services and outreach into existing services
- Enhance peer support strategies, such as the use of clubs
- Provide alternative clinic hours, if possible
- Collect additional contact information for each client
- Provide clients in advance with referral partners in the event that they migrate, or provide with additional stock/prescription

**4.3. Monitoring and Evaluation of Clinical PrEP Provision**

Initial PrEP programmes should be accompanied by significant monitoring and evaluation (M&E) plans to measure programme roll-out and the success of various implementation approaches, and also to capture lessons learned on the many unanswered questions regarding the best methods for screening and initiating clients and client monitoring (refer to the PrEP and T&T implementation plan).
5. About the Development of the PrEP and Test & Treat Guidelines

On 23 October 2015, a meeting was held at the National Department of Health to discuss the programmatic implications for adopting and implementing the new WHO guidelines for Test and Treat (T&T) and HIV Pre-Exposure Prophylaxis (PrEP). During that meeting it was decided that a core group of experts would convene to review evidence, programmatic implications, and develop national guidelines for PrEP.

The core group met on 23-24 November 2015 to prepare the draft PrEP guidelines. The Southern Africa HIV Clinicians Society PrEP guidelines were used as the basis of the clinical section. The draft guidelines were shared with the expert community on 15 December 2015. Comments were incorporated and a revised version was shared with Dr Pillay. Upon receipt of comments from Dr Pillay, and recognising a number of outstanding issues still needed to be addressed, a third meeting with a larger group of experts and representatives from the South Africa HIV programme community was held on 13 January 2016 at the National Department of Health.

Based on the outcome of the January meeting, a revised version of guidelines, as well as a draft policy, was shared with the larger group for comment in early February. Feedback was incorporated and the revised guidelines and policy were discussed with the larger technical working group members in a meeting on 25 February 2016.

In coordination with the launching of the South African National Sex Worker HIV Plan on 11 March 2016, a revised version of the PrEP and Test and Treat guidelines were developed, which focused on the provision of PrEP and T&T services, in the context of combination prevention and expanded treatment, for the sex worker population. The new, focused guidelines were shared with the expert group and discussed at a NDOH meeting, chaired by Dr Pillay, on 10 March 2016.
6. Appendixes

Appendix 1. Evidence and Benefits of PrEP
Appendix 2. Costing and Implementation
Appendix 3. Organizations and Stakeholders Involved in the Drafting of the PrEP Guidelines
Appendix 4. Ongoing and Planned PrEP Trials and Demonstration Projects
7. References

2. DHIS, March 2015
10. SANAC. National Strategic Plan for HIV Prevention, Care and Treatment for Sex Workers. Pretoria;; 2013.
13. Ibid.
22. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, September 2015.
24. Test and treat is already provided to XXX
25. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, September 2015.


First published online: January 13, 2015


41 Operational Guidelines for HIV, STI and TB Programmes for Key Populations in South Africa, National Department of Health, Version 0.5.3, September 2012.